| Document |
Document Title |
|
WO/2023/011028A1 |
The present invention relates to an organic compound, an electronic component and an electronic device. The structural formula of the organic compound of the present invention is represented by formula (I), and when used in an organic el...
|
|
WO/2023/014938A1 |
The present disclosure provides linker compounds of Formula (I) or (II) pharmaceutically acceptable salts thereof, and related scaffolds and conjugates. More specifically, linker compounds of formulas (l-A), (Il-A) are provided: The pres...
|
|
WO/2023/011634A1 |
The present invention relates to a benzo-ring-containing derivative, and a preparation method therefor and the use thereof. Specifically, the present invention relates to a compound as represented by general formula (Ia), and a preparati...
|
|
WO/2023/014553A1 |
Disclosed herein is a retrofit process to make 5-(alkoxycarbonyl)furan- 2-carboxylic acids (ACFC) from feedstocks comprised of furoates. When a feedstock comprised of methyl 5-methylfuran-2-carboxylate (MMFC) is used a product comprised ...
|
|
WO/2023/006908A1 |
The present invention relates to the field of organic synthesis and, more specifically, it concerns a process for the preparation of an oxacylopentane or oxacylohexane derivative of formaul (II) comprising the cyclodehydration of a 1,4- ...
|
|
WO/2023/007188A1 |
The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, Formula (I), wherein, the group X-Y is -NHSO2-; Z is a monocyclic or polycyclic cycloalkyl group or a monocyclic or pol...
|
|
WO/2023/005587A1 |
Disclosed in the present invention is a synthesis method for an empagliflozin key intermediate. According to the present invention, (5-bromo-2-chlorophenyl)(4-fluorophenyl)methanone forms an ether with L-dimethyl malate under the effect ...
|
|
WO/2023/005099A1 |
Disclosed in the present invention are an α-naphtholphthalein derivative multifunctional fluorescent probe, a preparation method therefor, and an application thereof. The structural formula of the fluorescent probe is as shown in formul...
|
|
WO/2023/008610A1 |
The present invention relates to a heterogeneous catalyst for making a dicarboxyl acid aromatic heterocyclic compound and a method for preparing a dicarboxyl acid aromatic heterocyclic compound. According to the present invention, an oxi...
|
|
WO/2023/008611A1 |
The present invention relates to a method for preparing a dicarboxyl acid aromatic heterocyclic compound and a dicarboxyl acid aromatic heterocyclic compound obtained thereby. According to the present invention, an oxide with improved yi...
|
|
WO/2023/007042A1 |
The present invention relates to the use of 3-arylphthalides and derivatives thereof as anti-inflammatory agents. The invention relates to the use of 3-arylphthalides, in particular 3-(4,5-dihydroxy-2-(2-5 ethylthio)ethylphenyl)phthalide...
|
|
WO/2023/003234A1 |
The present invention provides: a novel compound capable of improving the luminous efficiency, stability and lifespan of an element; an organic electric element using same; and an electronic device thereof.
|
|
WO/2023/003313A1 |
The present invention relates to: an organic compound which is used for an organic layer, such as a hole transport layer or an electron blocking layer, in an organic light-emitting device; and an organic light-emitting device comprising ...
|
|
WO/2023/001905A1 |
The present invention refers to a compound having the formula (I): R1–Z–C≡C–C≡C–R3 (I) and pharmaceutical compositions comprising the same that can be used in prevention, treatment and alleviation of a fungal infection. The i...
|
|
WO/2023/001164A1 |
A compound for treating an ischemic brain injury-related disease. The structure of the compound is as represented by formula (II) below. The compound is high in bioavailability and high in distribution concentration in rat plasma and bra...
|
|
WO/2023/001028A1 |
A heteroaryl-3-piperidinedione compound and the use thereof. Particularly disclosed are a compound represented by formula (II) and a pharmaceutically acceptable salt thereof.
|
|
WO/2023/288035A1 |
A process for carboxylation of a furoate slurry to produce FDCA, especially 2,5-FDCA, includes the steps of: feeding a slurry containing a suspension fluid, furoate, a surfactant and an alkali metal carbonate to a carboxylation reactor; ...
|
|
WO/2023/287704A1 |
Provided herein are compounds that bind to BF3 of an androgen receptor (AR), which can modulate the AR for the treatment of Kennedy's disease and for the treatment of cancer.
|
|
WO/2023/285883A1 |
Disclosed herein are embodiments of a bi-functionalized dicyclopentadiene monomer and polymer embodiments formed therefrom. The monomer embodiments exhibit tunability and can be used to form thermally stable homopolymers, copolymers, and...
|
|
WO/2023/288013A2 |
The present invention is directed to novel chemical compositions of matter, and in particular novel MDMA class of compounds having substituted methylenedioxyphenethylamine and substituted amphetamine, having a metabolically labile thioet...
|
|
WO/2023/286816A1 |
The present invention provides: a material which enables a photoelectric conversion element for image pickup to have higher sensitivity and higher resolution; and a photoelectric conversion element for image pickup, which uses this mater...
|
|
WO/2023/285788A1 |
A process for preparing a compound of formula (I), or a salt thereof, as defined herein. Also, compounds of formula I and intermediate compounds useful in the preparation of a compound of formula (I).
|
|
WO/2023/283207A1 |
An improved process and catalyst are provided for making an FDCA diester monomer product with improved productivity compared to an autocatalyzed esterification but with comparable or at least not greatly diminished color properties compa...
|
|
WO/2023/280155A1 |
Disclosed are a compound of formula (I), wherein the variables are defined in the specification, a pharmaceutical composition containing the same, and a method and a use of the compound or composition in the treatment of a PCSK9-mediated...
|
|
WO/2023/282046A1 |
The present disclosure provides a compound represented by general formula (I). (In the formula, Ar represents an aromatic group. R1 and R2 each independently represent a hydrogen atom, a halogen atom, a cyano group, a nitro group, an alk...
|
|
WO/2023/279280A1 |
Disclosed in the present invention are an inhibitor of 1-methyl-7-chloro-4-((methoxyaryl heteroyl)amino)-N-(arylsulfonyl)-indole-2-carboxamide FBPase having a novel structure, a preparation method therefor, and a pharmaceutical compositi...
|
|
WO/2023/282045A1 |
The present disclosure provides a compound represented by general formula (I). (I) (In the formula, Ara is a group obtained by removing n1 hydrogen atoms from a structure represented by general formula (A), and is bonded to R1 at a porti...
|
|
WO/2023/273997A1 |
An organic compound and an application thereof. The organic compound has a structure represented by formula I, has better stability and photoelectric properties, and can enhance and balance carrier transport, thereby improving device per...
|
|
WO/2023/276983A1 |
The present disclosure provides: a novel synthesis intermediate for beraprost or an optically active form thereof; and a production method using the synthesis intermediate. More specifically, in the present disclosure, a compound represe...
|
|
WO/2022/268563A1 |
The invention relates to compounds of formula (I), and their use as herbicides. In said formula, R1 to R8 represent groups such as hydrogen, halo-gen or organic groups such as alkyl, alkenyl, alkynyl, or alkoxy; W1 and W2 are -CR9R10-, -...
|
|
WO/2022/270982A1 |
The present invention relates to a method for producing tetrahydrofuran, gamma-butyrolactone, or 1,4-butanediol. Particularly, according to an embodiment of the present invention, by using polyhydroxyalkanoate (PHA), the yield of tetrahy...
|
|
WO/2022/268564A1 |
The invention relates to compounds of formula (I), and their use as herbicides. In said formula, R1 to R10 represent groups such as hydrogen, halo-gen or linear or cyclic organic groups such as alkyl, alkenyl, alkynyl, cycloalkyl, or alk...
|
|
WO/2022/270430A1 |
Provided is a mixed powder containing a first compound and a second compound. The first compound is such that the number of rings in the condensed ring structure, from among the condensed ring structures included in the compound, having ...
|
|
WO/2022/270428A1 |
This mixed powder for an organic electroluminescent element contains a first organic compound and a second organic compound, and is a solid at normal temperature and normal pressure. When the molar concentration of the first organic comp...
|
|
WO/2022/270423A1 |
This mixed powder for an organic electroluminescent element contains a first organic compound and a second organic compound, and is a solid at normal temperature and normal pressure. When the molar concentration of the first organic comp...
|
|
WO/2022/267661A1 |
The present application belongs to the field of organic materials, and relates to an organic compound, and an electronic element and an electronic device using same. The organic compound has a structure as represented by formula 1, and t...
|
|
WO/2022/269049A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, A, L1, L2, Y and Z are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formu...
|
|
WO/2022/268021A1 |
The present invention provides a Cu-based catalyst and a use thereof for photocatalytic water-based hydrogen production-5-hydroxymethylfurfural (HMF) oxidation coupling reaction. The chemical expression of the Cu-based catalyst is Cu/CoA...
|
|
WO/2022/268525A1 |
A process for hydrogenating an ester of the general formula (III) with molecular hydrogen to the alcohols (a) and (b) at a temperature of 50 to 200°C and a pressure of 0.1 to 20 MPa abs in the presence of a manganese(I) complex, the man...
|
|
WO/2022/263605A1 |
It is described the use of a compound according to formula (I) as precursor in perfumery for generating a ketone or aldehyde of formula (II).
|
|
WO/2022/263150A1 |
The invention relates to compositions comprising n-nonanoic acid esters of xylitan and/or sorbitan, a method for their production, formulations comprising them and their use.
|
|
WO/2022/265993A1 |
This disclosure provides compounds of Formula (I), Formula (II), and pharmaceutically acceptable salts thereof, that inhibit phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) isoform alpha (PI3Ka). These chemical entities are useful,...
|
|
WO/2022/262365A1 |
The present application relates to an organic compound, and an electronic element and electronic device comprising same. The structural formula of the organic compound of the present application is represented by formula 1, and the appli...
|
|
WO/2022/262657A1 |
The present invention relates to an N-substituted phenylsulfonamide compound and a use thereof. Specifically, the present invention provides a compound represented by formula I, or an optical isomer thereof, or a racemate thereof, or a p...
|
|
WO/2022/258792A1 |
The present invention relates to new cinnamic add amides which may be used for treatment of fibrosis and neoplasia and to cinnamic acid amides for use in the treatment of fibrosis, neoplasia, arthrolithiasis, familiar mediterranean fever...
|
|
WO/2022/261624A1 |
Methods of safely administrating a matrix metalloproteinase 12 (MMP-12) inhibitor by oral administration are described. Also described are methods for providing clinically proven safe treatment of asthma, chronic obstructive pulmonary di...
|
|
WO/2022/257271A1 |
The present invention relates to the synthesis of eribulin mesylate, and specifically provides a method for preparing an intermediate compound of eribulin mesylate represented by formula II ((1R,2S,3S,4S,5S,6R,11S,14S,17S,19R,21R,23S,25R...
|
|
WO/2022/257584A1 |
The present invention relates to a compound, which has a structural formula shown in formula (I) and is suitable for use in electronic components, especially in organic electroluminescence devices, and relates to a material for organic e...
|
|
WO/2022/261623A1 |
Methods of treating acute respiratory distress syndrome (ARDS) by administration of a matrix metalloproteinase (MMP) inhibitor are described.
|
|
WO/2022/260240A1 |
The present specification provides a heterocyclic compound represented by chemical formula 1, and an organic light-emitting device comprising same.
|
